Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bacterial surface anionic polymers are a diverse group of negatively charged glycopolymers essential for the structural integrity and physiological function of the bacterial cell envelope. In Gram-positive bacteria, these are primarily represented by wall teichoic acids (WTA) and lipoteichoic acids (LTA), whereas in Gram-negative bacteria, lipopolysaccharides (LPS) serve as the dominant anionic component (Raetz & Whitfield, 2002; Brown et al., 2013). These polymers contribute to the net negative charge of the bacterial surface, facilitating the sequestration of essential divalent cations like Mg2+ and Ca2+, which stabilize the membrane and support enzymatic activities (Brown et al., 2013). They are critical for processes such as cell wall morphogenesis, biofilm formation, and adherence to host cells during infection (Weidenmaier & Peschel, 2008). Therapeutically, these polymers are targeted by several classes of antibiotics; for instance, polymyxins bind to the lipid A component of LPS, while daptomycin's activity is linked to its interaction with LTA and the cytoplasmic membrane (Trimble et al., 2016; Heidary et al., 2018). Additionally, these molecules are potent triggers of the innate immune system, acting as ligands for Toll-like receptors (TLR2 and TLR4) to initiate inflammatory cascades (Akira & Takeda, 2004). Targeting the biosynthesis of these polymers, particularly WTAs, is an emerging strategy to restore antibiotic sensitivity in resistant strains like MRSA (Campbell et al., 2011).
Drugs target these polymers through electrostatic interactions that disrupt membrane integrity or by inhibiting the biosynthetic pathways of these essential cell wall components.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bacterial surface anionic polymer.